As more gene and cell therapies enter the market at increasingly higher price points, they are ushering in a new era of medicine for rare diseases. Unlike most traditional therapies, gene and cell therapies typically have a short or one-time treatment administration and are anticipated to provide long-term clinical benefits. Actuaries must be prepared to assess, manage, and/or mitigate the risks associated with these therapies. This session includes three different perspectives - a regional plan, a stop/loss reinsurance carrier, and a health care consultant. This session intends to cover (1) the sources of risk associated with gene and cell therapies from a healthcare payer's perspective, (2) approaches for evaluating a plan's exposure, and (3) types and challenges of different risk management approaches (e.g., reinsurance, value-based/outcomes-based contracts, risk pools).
By attending this session, you will be able to:
Identify the sources of risk associated with gene and cell therapies from a healthcare payer's perspective.
Have a framework of approaches for evaluating a plan's exposure to gene and cell therapies.
Understand types of risk management approaches and the challenges associated with each.
Take part in a deeper discussion on this topic and more at Oysters, Beers & Large Claim Solutions on Tuesday, June 27, from 4:30-5:30 p.m. PT. This happy hour, featuring drinks and tasty Pacific Northwest oysters will include a discussion on the large claims impacts on the healthcare market.